2Smits P. Thien T. Cardiovascular effects of suplphonylurea derivatives. Diabetologia 1995; 38:116 - 121.
3Leibowitz G. Cerasi E. Sulphonylurea treatment on NIDDM Patients with cardiovascular disease: a mixed blessing? Diabetologia 1996;39:503 - 514.
4Tumer R, Cull C, Holman R(UKPDS Group). UKPDS 17: a 9 year update of a randomized. controlled trial on the effect of improved metabolic control on complications in DIDDM. Ann Intern Med 1996; 124:136 - 145.
7Dubois M, Vantyghem MC, Schoonjans K, et al. Thiazolidnediones in type 2 diabetes. Role of peroxisome proliferator- activated recepotr gamma ( PPAR gamma). Ann Endocrinal(Paris) 2002; 63: 511- 523.
二级参考文献5
1王蔼明，中华妇产科杂志，1998年，33卷，280页
2石湘芸，体液因素与临床疾病，1997年，296页
3Charpentier G,Vaur L,Halimi S,et al.Predictor of response to glimepiride in patients with type 2 diabetes mellitus[].Diabetes and Metabolism.2001
4Schade DS,Jovanovic L,Schneide J.A placebo-controlled,randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful[].Journal of Clinical Pharmacology.1998
5Raptis SA,Hatziagelaki E,Dimitriadis G,et al.Comparative effects of glimepiride and glibenclamide on blood glucose, C-peptide and insulin concentrations of the fasting and postprandial state in normal men[].Experimental and Clinical Endocrinology and Diabetes.1999
